M. Pétri

1.7k total citations
27 papers, 1.2k citations indexed

About

M. Pétri is a scholar working on Rheumatology, Immunology and Oncology. According to data from OpenAlex, M. Pétri has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Rheumatology, 12 papers in Immunology and 5 papers in Oncology. Recurrent topics in M. Pétri's work include Systemic Lupus Erythematosus Research (22 papers), T-cell and B-cell Immunology (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). M. Pétri is often cited by papers focused on Systemic Lupus Erythematosus Research (22 papers), T-cell and B-cell Immunology (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). M. Pétri collaborates with scholars based in United States, United Kingdom and Argentina. M. Pétri's co-authors include Jill Allbritton, Nelson B. Schiller, Jay Simonson, David B. Hellmann, Kyriakos A. Kirou, C. Le, S.M. Berney, Wendy I. White, Gabriel J. Robbie and Jim C. Oates and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Lupus.

In The Last Decade

M. Pétri

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Pétri United States 17 850 607 210 188 160 27 1.2k
Beverley Harrison United Kingdom 20 1.5k 1.8× 397 0.7× 191 0.9× 248 1.3× 67 0.4× 29 1.9k
Christopher Collins United States 14 523 0.6× 495 0.8× 190 0.9× 169 0.9× 60 0.4× 25 930
Karina de Leeuw Netherlands 20 651 0.8× 627 1.0× 107 0.5× 172 0.9× 170 1.1× 64 1.4k
Sébastien Viatte United Kingdom 19 577 0.7× 640 1.1× 163 0.8× 150 0.8× 282 1.8× 54 1.7k
B. A. C. Dijkmans Netherlands 13 1.5k 1.8× 394 0.6× 238 1.1× 130 0.7× 88 0.6× 24 1.9k
Salem Almaani United States 13 824 1.0× 529 0.9× 107 0.5× 65 0.3× 167 1.0× 36 1.3k
Damon Bass United States 14 1.1k 1.3× 753 1.2× 526 2.5× 112 0.6× 120 0.8× 28 1.4k
Baudouin Leclercq United States 12 541 0.6× 177 0.3× 90 0.4× 91 0.5× 146 0.9× 19 1.1k
Laura Massaro Italy 19 768 0.9× 355 0.6× 166 0.8× 150 0.8× 49 0.3× 46 990
György Kerekes Hungary 19 869 1.0× 476 0.8× 99 0.5× 219 1.2× 126 0.8× 49 1.5k

Countries citing papers authored by M. Pétri

Since Specialization
Citations

This map shows the geographic impact of M. Pétri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Pétri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Pétri more than expected).

Fields of papers citing papers by M. Pétri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Pétri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Pétri. The network helps show where M. Pétri may publish in the future.

Co-authorship network of co-authors of M. Pétri

This figure shows the co-authorship network connecting the top 25 collaborators of M. Pétri. A scholar is included among the top collaborators of M. Pétri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Pétri. M. Pétri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pétri, M., Eszter Csomor, Philip Z. Brohawn, et al.. (2024). POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS. Annals of the Rheumatic Diseases. 83. 292–293. 1 indexed citations
2.
Magder, Laurence S., et al.. (2015). FRI0405 Prednisone Increases Both Arterial and Venous Thrombosis in SLE. Annals of the Rheumatic Diseases. 74. 573–573.
3.
Fangtham, Monthida, LS Magder, & M. Pétri. (2014). Oral candidiasis in systemic lupus erythematosus. Lupus. 23(7). 684–690. 22 indexed citations
4.
Richard, Florence, Morton Scheinberg, Alvina D. Chu, et al.. (2014). FRI0388 Effects of Blisibimod on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies. Annals of the Rheumatic Diseases. 73. 527–528. 1 indexed citations
5.
Kiani, Adnan N., et al.. (2013). Predictors of self-reported health-related quality of life in systemic lupus erythematosus. Lara D. Veeken. 52(9). 1651–1657. 52 indexed citations
6.
7.
Wallace, DJ, Sandra Navarra, M. Pétri, et al.. (2012). Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 22(2). 144–154. 88 indexed citations
8.
Merrill, JT, M. Pétri, Kyriakos A. Kirou, et al.. (2011). Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Annals of the Rheumatic Diseases. 70(11). 1905–1913. 191 indexed citations
9.
Singh, Sonal, et al.. (2008). Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus. 17(2). 114–123. 20 indexed citations
10.
Pétri, M.. (2008). Sex hormones and systemic lupus erythematosus. Lupus. 17(5). 412–415. 70 indexed citations
11.
Pétri, M.. (2007). Disease activity assessment in SLE: do we have the right instruments?. Annals of the Rheumatic Diseases. 66. iii61–iii64. 57 indexed citations
12.
Pétri, M.. (2004). Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus. 13(5). 366–371. 72 indexed citations
13.
Goldman, Daniel, et al.. (2001). Interferon-γ polymorphisms in systemic lupus erythematosus. Genes and Immunity. 2(5). 254–257. 33 indexed citations
14.
Verthelyi, Daniela, et al.. (2001). Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus. 10(5). 352–358. 38 indexed citations
15.
Sullivan, Kathleen E., et al.. (2000). A TNFR2 3′ flanking region polymorphism in systemic lupus erythematosus. Genes and Immunity. 1(3). 225–227. 4 indexed citations
16.
Battaglia, Agatino, et al.. (1999). Analisi dell'influenza del trattamento con venlafaxina sull'outcome cognitivo in pazienti con depressione post-stroke : risultati di uno studio clinico randomizzato, controllato in doppio cieco. 9(1). 15–27. 2 indexed citations
17.
Gladman, Dafna D., Murray B. Urowitz, Paul R. Fortin, et al.. (1996). Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group.. PubMed. 23(11). 1953–5. 69 indexed citations
18.
Kirsch, C. M., Quinn E. Whiting-O'Keefe, Joseph L. Simonson, et al.. (1995). Dyspnea in ambulatory patients with SLE: prevalence, severity, and correlation with incremental exercise testing.. PubMed. 22(3). 455–61. 19 indexed citations
19.
Pétri, M. & Jill Allbritton. (1993). Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort.. PubMed. 20(4). 650–6. 123 indexed citations
20.
Simonson, Jay, Nelson B. Schiller, M. Pétri, & David B. Hellmann. (1989). Pulmonary hypertension in systemic lupus erythematosus.. PubMed. 16(7). 918–25. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beverley Harrison Breakdown of academic impact, for papers by Christopher Collins Breakdown of academic impact, for papers by Karina de Leeuw Breakdown of academic impact, for papers by Sébastien Viatte Breakdown of academic impact, for papers by B. A. C. Dijkmans Breakdown of academic impact, for papers by Salem Almaani Breakdown of academic impact, for papers by Damon Bass Breakdown of academic impact, for papers by Baudouin Leclercq Breakdown of academic impact, for papers by Laura Massaro Breakdown of academic impact, for papers by György Kerekes
Rankless by CCL
2026